FindTrial
Sign In

Identification of factors predicting complete response to neo-adjuvant chemotherapy in breast cancer patients

Development of predictive nomogram for assessing pathological complete response after neo-adjuvant chemotherapy in treatment naive non-metastatic breast cancer patients - An ambispective study - P-NNACLE-B (P-Predictive N-Nomogram post N-Neo A-Adjuvant C-Chemotherapy in L-Locally advanced and E-Early B-Breast cancer)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/12/078269
Enrollment
380
Registered
2024-12-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Control Intervention1: nil: nil

Sponsors

All India Institute of Medical Sciences, New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Treatment naïve non-metastatic breast cancer patients receiving/received neoadjuvant chemotherapy 2. For prospective group: patients consenting to participate in the study

Exclusion criteria

Exclusion criteria: 1. Breast cancer patients with previous history of surgery or radiotherapy to chest and axilla. 2. Metastatic breast cancer at presentation. 3. Patients not consenting to participate in the study. 4. Patients having incomplete records.

Design outcomes

Primary

MeasureTime frame
To develop a predictive nomogram to predict pathological complete response in treatment naïve non metastatic breast cancer patients receiving neoadjuvant chemotherapyTimepoint: From enrollment to final histopathology (06 months)—

Secondary

MeasureTime frame
To validate the predictive nomogram developed to identify the patients having a likelihood of achieving pathological complete response in treatment naïve non metastatic breast cancer patients receiving neoadjuvant chemotherapyTimepoint: 01 month;To study the factors predicting pathological complete response in treatment naïve non metastatic breast cancer patients receiving neoadjuvant chemotherapyTimepoint: 06 months—

Countries

India

Contacts

Public ContactDr Ramita Mukherjee

All India Institute of Medical Sciences, New Delhi

drramitamukherjee@gmail.com7604052439

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026